InvestorsHub Logo
Followers 2
Posts 385
Boards Moderated 0
Alias Born 09/20/2017

Re: skitahoe post# 2424

Sunday, 08/26/2018 8:59:34 PM

Sunday, August 26, 2018 8:59:34 PM

Post# of 3988
Gary for me is the key paragraph following

There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition.

Applicable to the Protalix IMO this means there is no comparable or satisfactory therapy for Fabry patients with progressing impaired renal function.The company talks about this a long time. Expanded Access program is another confirmation of this.It's definitely good news for us shareholders.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News